Helsinn Healthcare S.A.: Helsinn Group announces oral presen

Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor Lugano, Switzerland, 7 October 2021 - Helsinn

Related Keywords

China , Lugano , Ticino , Switzerland , Japan , Swiss , Isao Miyazaki , Kostenloser Wertpapierhandel , Paola Bonvicini , Johns Hopkins , Sergio Cantoreggi , Ireland Helsinn Birex Pharmaceuticals Ltd , Linkedin , Us Helsinn Therapeutics Inc , Taiho Pharmaceutical Co Ltd , Twitter , Virtual International Conference On Molecular , China Helsinn Pharmaceuticals Beijing Co Ltd , Group Head Of Communication , Swiss Biopharmaceutical Group , Helsinn Group Media Contact , Group Head , Helsinn Group , Otsuka Holdings Co Ltd , International Conference , Molecular Targets , Cancer Therapeutics , New Drugs , Group Chief Scientific Officer , Non Small Cell Lung Cancer , Cancer Biol Ther , Cell Rep , Nat Med , Nat Rev Clin Oncol , Onco Targets Ther , Helsinn Therapeutics , Helsinn Pharmaceuticals , Helsinn Birex Pharmaceuticals Ltd , Taiho Pharmaceutical , Group Media Contact , Helsinn , Healthcare , Group , Nnounces , Mural , Presentation , Data , Racr , Hortc , Elating , Kpotent , Ighly , Elective , Investigational , Inhibitor ,